Ridge Sarah M, Sullivan Francis J, Glynn Sharon A
Discipline of Pathology, Lambe Institute for Translational Research, School of Medicine, Costello Road, Galway, Ireland.
Prostate Cancer Institute, School of Medicine, Costello Road, Galway, Ireland.
Mol Cancer. 2017 Feb 1;16(1):31. doi: 10.1186/s12943-017-0597-8.
Tumour progression is dependent on the interaction between tumour cells and cells of the surrounding microenvironment. The tumour is a dynamic milieu consisting of various cell types such as endothelial cells, fibroblasts, cells of the immune system and mesenchymal stem cells (MSCs). MSCs are multipotent stromal cells that are known to reside in various areas such as the bone marrow, fat and dental pulp. MSCs have been found to migrate towards inflammatory sites and studies have shown that they also migrate towards and incorporate into the tumour. The key question is how they interact there. MSCs may interact with tumour cells through paracrine signalling. On the other hand, MSCs have the capacity to differentiate to various cell types such as osteocytes, chondrocytes and adipocytes and it is possible that MSCs differentiate at the site of the tumour. More recently it has been shown that cross-talk between tumour cells and MSCs has been shown to increase metastatic potential and promote epithelial-to-mesenchymal transition. This review will focus on the role of MSCs in tumour development at various stages of progression from growth of the primary tumour to the establishment of distant metastasis.
Mol Cancer. 2017-2-1
Anticancer Res. 2020-6
Cancer Discov. 2016-8
Biochim Biophys Acta. 2016-12
Curr Stem Cell Res Ther. 2019
J Natl Cancer Cent. 2025-3-27
Exp Hematol Oncol. 2025-7-17
Curr Stem Cell Res Ther. 2025
Cancer Cell Int. 2025-4-29
MedComm (2020). 2025-4-24
BMC Cancer. 2025-4-14
J Clin Med. 2017-1-6
Nat Rev Cancer. 2016-8-23
J Exp Clin Cancer Res. 2015-5-20
Breast Cancer Res. 2015-3-20
Cancer Immunol Res. 2015-1
Stem Cell Res Ther. 2014-8-12